PBM Market Competition Will Remain 'Robust' After CVS-Aetna Merger, House Panel Told
Executive Summary
CVS General Counsel Thomas Moriarty maintained merger will not involve consolidation of PBM market share.
You may also be interested in...
PBMs Play Outsized Role … In Hearing On Health Sector Consolidation
PBMs have become a central focus of the drug pricing debate, thanks in large part to the biopharma industry’s efforts to shine a spotlight on the role of rebates and middlemen in consumer costs. They were also a surprising focus on a hearing about health industry consolidation.
CVS/Aetna Deal Faces Challenge of Appeasing Current PBM Clients
Big, revolutionary, vertical deals to change structure of health industry are dramatic but tough to pull off. Will CVS PBM customers worry about funding a competitor?
CVS/Aetna To Merge In Defensive Play To Reshape Healthcare Delivery
The pharmacy retail chain and drug distributor will buy the insurer for $69bn in a merger to build what the companies say will be a new, more affordable healthcare concept.